一项2b期随机双盲比较研究:抗狂犬病单克隆抗体混合物SYN023与狂犬病人免疫球蛋白在狂犬病暴露患者中的安全性和有效性
在潜在狂犬病暴露后54小时内,448例WHO III级暴露患者随机接受0.3 mg/kg SYN023或0.133 mL/kg人狂犬病免疫球蛋白(HRIG)伤口周围注射并接种狂犬病疫苗。SYN023组在第4天和第8天达到保护性狂犬病毒中和抗体(RVNA)水平的比例高于HRIG组,第99天RVNA几何平均滴度低于HRIG但保护性应答比例非劣效,两组均无狂犬病病例,安全性可接受。
要点
- 第4天SYN023组99.4%患者达保护性RVNA水平,HRIG组为4.5%。
- 第8天SYN023组98.1%患者达保护性RVNA水平,HRIG组为12.2%。
- 第99天SYN023:HRIG保护性应答比例比为0.98,满足20%非劣效界值(P=0.013)。
核心结论
- SYN023在狂犬病暴露后早期提供的RVNA水平高于HRIG。
- 至治疗后第99天,SYN023组的RVNA几何平均滴度低于HRIG组,但该时间点达到保护性应答的患者比例非劣效于HRIG。
- 研究中未报告狂犬病病例,SYN023安全性特征可接受。
研究设计与样本
- 2b期随机双盲比较研究,纳入潜在狂犬病暴露后54小时内的448例WHO III级暴露患者,按两个风险亚层随机分组。
- 患者接受0.3 mg/kg SYN023或0.133 mL/kg人狂犬病免疫球蛋白(HRIG)在伤口部位及周围注射,并完成狂犬病疫苗接种疗程。
- 随访安全性及无狂犬病状态至少365天。
- 主要分析组共368例。
主要发现
- 主要分析组(n=368)中,第4天SYN023组99.4%患者达到保护性RVNA水平,HRIG组为4.5%。
- 第8天SYN023组98.1%患者达到保护性RVNA水平,HRIG组为12.2%。
- 第8天SYN023:HRIG的RVNA几何平均滴度比为19.42,超过10%优效界值(P < 0.0001),表明SYN023组第8天RVNA更高。
- 第99天SYN023:HRIG的RVNA几何平均滴度比为0.66,低于20%非劣效界值(P = 0.9485),提示SYN023相对于HRIG对疫苗免疫应答有一定减弱。
- 第99天达到RVNA ≥ 0.5 IU/mL的SYN023:HRIG患者百分比比为0.98,满足20%非劣效界值(P = 0.013),表明尽管存在上述效应,SYN023的抗狂犬病免疫应答非劣效于HRIG。
关键数值与推荐
- 狂犬病毒中和抗体(RVNA)浓度≥ 0.5 IU/mL一般被认为是疫苗接种后的 adequate 免疫应答。
- 第4天保护性RVNA水平:SYN023组99.4% vs HRIG组4.5%(主要分析组n=368)。
- 第8天保护性RVNA水平:SYN023组98.1% vs HRIG组12.2%。
- 第8天RVNA几何平均滴度比SYN023:HRIG为19.42(P < 0.0001),超过10%优效界值。
- 第99天RVNA几何平均滴度比SYN023:HRIG为0.66(P = 0.9485),低于20%非劣效界值;第99天RVNA ≥ 0.5 IU/mL患者百分比比SYN023:HRIG为0.98(P = 0.013),满足20%非劣效界值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SYN023 is an anti-rabies monoclonal antibody mixture administered as part of post-exposure prophylaxis regimens. The rabies virus neutralizing antibody (RVNA) concentration generally accepted as an adequate immune response to vaccination is ≥ 0.5 IU/mL. METHODS: Within 54 h of potential rabies exposure, 448 patients in two risk substrata of WHO Category III exposure were randomized to receive either 0.3 mg/kg SYN023 or 0.133 mL/kg human rabies immunoglobulin (HRIG) injected in and around the wound site(s) plus a course of rabies vaccination. Patients were followed for safety and absence of rabies for ≥ 365 days. RESULTS: GMT RVNA was higher with SYN023 throughout the 2-week post-treatment period. In the primary analysis group (n = 368), 99.4 % of SYN023 recipients versus 4.5 % of HRIG recipients had protective RVNA levels on Day 4. On Day 8, 98.1 % SYN023 versus 12.2 % HRIG recipients were protected. The SYN023:HRIG ratio of geometric mean titer of RVNA (RVNA GMTs) on Day 8 (19.42) exceeded the 10 % superiority margin (P < 0.0001) indicating higher Day 8 RVNA with SYN023. On Day 99, the SYN023:HRIG RVNA GMT ratio (0.66) was below the non-inferiority margin of 20 % (P = 0.9485) suggesting some moderation of vaccine immune response by SYN023 relative to HRIG. The ratio of percent SYN023:HRIG recipients achieving RVNA ≥ 0.5 IU/mL on Day 99 (0.98) met the non-inferiority margin of 20 % (P = 0.013) indicating anti-rabies immune response with SYN023 was non-inferior to HRIG despite this effect. There were no probable/confirmed rabies cases in any patient. Study regimens were well tolerated. CONCLUSIONS: SYN023 provided higher RVNA than HRIG soon after rabies exposure. By Day 99 post-treatment, GM RVNA with SYN023 was lower than HRIG, however, the percent of SYN023 recipients with a protective response was not inferior at this time point. No rabies cases were reported in the study. The SYN023 safety profile was acceptable. CLINICALTRIALS: gov ID: NCT03961555.
引用
- Quiambao BP, Payumo RA, Roa C, et al. A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies. Vaccine. 2024. PMID: 38834432. doi:10.1016/j.vaccine.2024.05.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。